Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of "Buy" by Brokerages

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) has earned a consensus recommendation of "Buy" from the thirteen analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $89.90.

Several equities research analysts have issued reports on JANX shares. Lifesci Capital raised shares of Janux Therapeutics to a "strong-buy" rating in a research note on Friday, December 27th. HC Wainwright raised their price target on shares of Janux Therapeutics from $63.00 to $70.00 and gave the stock a "buy" rating in a research note on Tuesday, December 3rd. William Blair reaffirmed an "outperform" rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Leerink Partnrs upgraded Janux Therapeutics to a "strong-buy" rating in a report on Friday, November 22nd. Finally, BTIG Research upped their price target on Janux Therapeutics from $82.00 to $100.00 and gave the company a "buy" rating in a research report on Tuesday, December 3rd.

Janux Therapeutics Price Performance

Janux Therapeutics stock traded down $1.42 during midday trading on Wednesday, reaching $43.93. The company had a trading volume of 605,526 shares, compared to its average volume of 1,326,414. Janux Therapeutics has a 12-month low of $7.79 and a 12-month high of $71.71. The company has a market capitalization of $2.31 billion, a P/E ratio of -37.55 and a beta of 3.23. The firm's fifty day simple moving average is $53.85 and its 200-day simple moving average is $48.37.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The firm had revenue of $0.44 million during the quarter, compared to analysts' expectations of $1.50 million. The business's revenue was down 82.6% compared to the same quarter last year. On average, analysts expect that Janux Therapeutics will post -1.35 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO David Alan Campbell sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total value of $300,000.00. Following the sale, the chief executive officer now directly owns 293,054 shares of the company's stock, valued at approximately $17,583,240. The trade was a 1.68 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Ventures Xi L.P. Avalon sold 1,843 shares of the company's stock in a transaction that occurred on Thursday, October 17th. The stock was sold at an average price of $50.02, for a total transaction of $92,186.86. Following the completion of the transaction, the insider now owns 6,371 shares in the company, valued at approximately $318,677.42. This represents a 22.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 110,177 shares of company stock valued at $6,162,207 over the last quarter. 29.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

A number of institutional investors have recently modified their holdings of JANX. Amalgamated Bank boosted its holdings in Janux Therapeutics by 61.1% during the 2nd quarter. Amalgamated Bank now owns 970 shares of the company's stock valued at $41,000 after acquiring an additional 368 shares during the period. Plato Investment Management Ltd acquired a new position in shares of Janux Therapeutics in the second quarter valued at approximately $42,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company's stock worth $87,000 after buying an additional 339 shares during the period. Avanza Fonder AB purchased a new stake in Janux Therapeutics during the 4th quarter worth approximately $139,000. Finally, AQR Capital Management LLC acquired a new stake in Janux Therapeutics during the 2nd quarter worth approximately $215,000. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.